Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome.
drug cost
economic evaluation of health policy
health care cost
infantile spasms
outcomes research
treatment
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
19
12
2022
received:
08
10
2022
accepted:
03
01
2023
pubmed:
6
1
2023
medline:
15
3
2023
entrez:
5
1
2023
Statut:
ppublish
Résumé
To describe the temporal trends in the cost and use of adrenocorticotropic hormone (ACTH), oral prednisolone, and vigabatrin, the first-line treatments for infantile epileptic spasms syndrome (IESS). Retrospective observational study using the MarketScan Commercial database from 2006 to 2020. We identified patients with IESS diagnosed between birth and 18 months of age who received at least one of the first-line treatments within 60 days of diagnosis. Costs were adjusted for inflation using the Gross Domestic Product Implicit Price Deflator. A total of 1131 patients received at least one first-line treatment (median [p The gap between the cost of ACTH and the cost of oral prednisolone or vigabatrin has widened markedly from 2006 to 2020, whereas the relative proportion of ACTH use has decreased.
Substances chimiques
Vigabatrin
GR120KRT6K
Anticonvulsants
0
Adrenocorticotropic Hormone
9002-60-2
Prednisolone
9PHQ9Y1OLM
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
630-640Informations de copyright
© 2023 International League Against Epilepsy.
Références
Jia JL, Chen S, Sivarajah V, Stephens D, Cortez MA. Latitudinal differences on the global epidemiology of infantile spasms: systematic review and meta-analysis. Orphanet J Rare Dis. 2018;13:216.
Gaily E, Lommi M, Lapatto R, Lehesjoki AE. Incidence and outcome of epilepsy syndromes with onset in the first year of life: a retrospective population-based study. Epilepsia. 2016;57:1594-601.
O'Callaghan FJ, Lux AL, Darke K, Edwards SW, Hancock E, Johnson AL, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom infantile spasms study. Epilepsia. 2011;52:1359-64.
O'Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017;16:33-42.
American Academy of NaCNS. Child neurology quality measurement set. 2017. Available from: https://cdn-links.lww.com/permalink/wnl/a/wnl_2017_11_28_patel_822643_sdc1.pdf.
Go CY, Mackay MT, Weiss SK, Stephens D, Adams-Webber T, Ashwal S, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the guideline development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78:1974-80.
Grinspan ZM, Knupp KG, Patel AD, Yozawitz EG, Wusthoff CJ, Wirrell E, et al. Comparative effectiveness of initial treatment for infantile spasms in a contemporary US cohort. Neurology. 2021;97:e1217-28.
Patel AD, Berg AT, Billinghurst L, Fain D, Fecske E, Feyma T, et al. Quality improvement in neurology: child neurology quality measure set: executive summary. Neurology. 2018;90:67-73.
Samanta D. Improving management of infantile spasms by adopting implementation science. Neuropediatrics. 2020;51:377-88.
Mytinger JR, Joshi S. Pediatric epilepsy research consortium SoIS. The current evaluation and treatment of infantile spasms among members of the Child Neurology Society. J Child Neurol. 2012;27:1289-94.
Jain P, Sahu JK, Horn PS, Chau V, Go C, Mahood Q, et al. Treatment of children with infantile spasms: a network meta-analysis. Dev Med Child Neurol. 2022;64:1330-43.
Sánchez Fernández I, Amengual-Gual M, Gainza-Lein M, Barcia Aguilar C, Bergin AM, Yuskaitis CJ, et al. Cost-effectiveness of adrenocorticotropic hormone versus oral steroids for infantile spasms. Epilepsia. 2021;62:347-57.
Gonzalez-Giraldo E, Stafstrom CE, Stanfield AC, Kossoff EH. Treating infantile spasms with high-dose oral corticosteroids: a retrospective review of 87 children. Pediatr Neurol. 2018;87:30-5.
Kossoff EH, Hartman AL, Rubenstein JE, Vining EP. High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH. Epilepsy Behav. 2009;14:674-6.
Hussain SA, Shinnar S, Kwong G, Lerner JT, Matsumoto JH, Wu JY, et al. Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone. Epilepsia. 2014;55:103-7.
Gettig J, Cummings JP, Matuszewski K. H.p. acthar gel and cosyntropin review: clinical and financial implications. P T. 2009;34:250-7.
Wray CD, Benke TA. Effect of price increase of adrenocorticotropic hormone on treatment practices of infantile spasms. Pediatr Neurol. 2010;43:163-6.
Grinspan ZM, Mytinger JR, Baumer FM, Ciliberto MA, Cohen BH, Dlugos DJ, et al. Management of infantile spasms during the COVID-19 pandemic. J Child Neurol. 2020;35:828-34.
Grinspan ZM, Mytinger JR, Baumer FM, Ciliberto MA, Cohen BH, Dlugos DJ, et al. Crisis standard of care: management of infantile spasms during COVID-19. Ann Neurol. 2020;88:215-7.
U.S. House or Representatives. Drug Pricing Investigation. Mallinckrodt-H.P. Acthar Gel. In: Congress of the United States. House of Representatives. 2020. Committee on oversight and reform, editor. Available from: https://oversight.house.gov/sites/democrats.oversight.house.gov/files/Mallinckrodt%20Staff%20Report%2010-01-20%20PDF.pdf
Watson Health. IBM MarketScan Research Databases for life sciences researchers. Available from: https://www.ibm.com/downloads/cas/OWZWJ0QO. 2022.
Berg AT, Chakravorty S, Koh S, Grinspan ZM, Shellhaas RA, Saneto RP, et al. Why west? Comparisons of clinical, genetic and molecular features of infants with and without spasms. PLoS One. 2018;13:e0193599.
Pellock JM, Hrachovy R, Shinnar S, Baram TZ, Bettis D, Dlugos DJ, et al. Infantile spasms: a U.S. consensus report. Epilepsia. 2010;51:2175-89.
Wang L, Yarosz S, Aghamoosa H, Grinspan Z, Patel AD. Validating an algorithm to identify patients with infantile spasms using medical claims. J Child Neurol. 2018;33:639-41.
Vigabatrin (pediatric and neonatal lexi-drugs) [database on the Internet]. 2022 [cited September, 1, 2022].
Corticotropin (pediatric and neonatal lexi-drugs) [database on the Internet]. 2022 [cited September, 1, 2022].
Prednisolone (systemic) (pediatric and neonatal lexi-drugs) [database on the Internet]. 2022 [cited September, 1, 2022].
Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: a review of measures for health services research in the United States. Health Serv Res. 2018;53:175-96.
Overman RA, Freburger JK, Assimon MM, Li X, Brookhart MA. Observation stays in administrative claims databases: underestimation of hospitalized cases. Pharmacoepidemiol Drug Saf. 2014;23:902-10.
Voss EA, Ma Q, Ryan PB. The impact of standardizing the definition of visits on the consistency of multi-database observational health research. BMC Med Res Methodol. 2015;15:13.
Hrachovy RA, Frost JD Jr, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr. 1983;103:641-5.
Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics. 1996;97:375-9.
Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2013;CD001770.
Chellamuthu P, Sharma S, Jain P, Kaushik JS, Seth A, Aneja S. High dose (4 mg/kg/day) versus usual dose (2 mg/kg/day) oral prednisolone for treatment of infantile spasms: an open-label, randomized controlled trial. Epilepsy Res. 2014;108:1378-84.
Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom infantile spasms study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364:1773-8.
Pollack A. Questcor finds profits, at $28,000 a vial. The New York Times. 2012. Available from: https://www.nytimes.com/2012/12/30/business/questcor-finds-profit-for-acthar-drug-at-28000-a-vial.html
Min JY, Knupp KG, Patel AD, Shellhaas RA, Zhang M, Grinspan ZM. Medication selection, health services outcomes, and cost trajectories for Medicaid beneficiaries with infantile spasms. Epilepsy Res. 2021;176:106733.
Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997;26:389-95.
Preventing epilepsy using vigabatrin in infants with tuberous sclerosis complex (PREVeNT Trial) a randomized, double-blind, placebo-controlled seizure prevention clinical trial for infants with TSC [database on the Internet]. 2016. [cited September, 29, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT02849457
Baumer FM, Mytinger JR, Neville K, Briscoe Abath C, Gutierrez CA, Numis AL, et al. Inequities in therapy for infantile spasms: a call to action. Ann Neurol. 2022;92:32-44.
Zodet MW, Hill SC, Miller E. Comparison of retail drug prices in the MEPS and MarketScan: implications for MEPS editing rules. Quality. AfHRa, editor. 2010.
Barnett PG. An improved set of standards for finding cost for cost-effectiveness analysis. Med Care. 2009;47:S82-8.
Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316:858-71.
Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar A, Bourdette DN. Industry payments to physician specialists who prescribe repository corticotropin. JAMA Netw Open. 2018;1:e180482.